このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Neuren Pharmaceuticals 過去の業績

過去基準チェック /66

Neuren Pharmaceuticalsは、平均年間77.4%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間47.3% 79.7%収益成長率で成長しています。 Neuren Pharmaceuticalsの自己資本利益率は76.5%であり、純利益率は67.7%です。

主要情報

77.4%

収益成長率

75.4%

EPS成長率

Pharmaceuticals 業界の成長	31.2%
収益成長率	79.7%
株主資本利益率	76.5%
ネット・マージン	67.7%
前回の決算情報	31 Dec 2023

Recent updates

収支内訳

Neuren Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

CHIA:NEU 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費
31 Dec 23	232	157	6
30 Sep 23	155	106	5
30 Jun 23	78	55	4
31 Mar 23	47	28	4
31 Dec 22	15	0	3
30 Sep 22	9	-3	3
30 Jun 22	3	-7	3
31 Mar 22	3	-7	3
31 Dec 21	3	-8	2
30 Sep 21	2	-10	2
30 Jun 21	1	-12	2
31 Mar 21	1	-11	2
31 Dec 20	1	-9	2
30 Sep 20	1	-8	2
30 Jun 20	0	-8	2
31 Mar 20	0	-9	2
31 Dec 19	0	-11	2
30 Sep 19	7	-6	2
30 Jun 19	14	-1	2
31 Mar 19	14	1	2
31 Dec 18	14	3	2
30 Sep 18	7	3	2
30 Jun 18	1	3	1
31 Mar 18	1	3	2
31 Dec 17	1	3	2
30 Sep 17	2	-2	2
30 Jun 17	3	-8	2
31 Mar 17	3	-10	2
31 Dec 16	3	-12	2
30 Sep 16	2	-14	2
30 Jun 16	0	-15	3
31 Mar 16	1	-14	3
31 Dec 15	2	-13	3
30 Sep 15	2	-11	3
30 Jun 15	3	-9	3
31 Mar 15	3	-9	3
31 Dec 14	3	-8	3
30 Sep 14	3	-10	2
30 Jun 14	3	-12	2
31 Mar 14	4	-11	2
31 Dec 13	5	-10	2
30 Sep 13	5	-9	3
30 Jun 13	5	-6	3

質の高い収益: NEUは高品質の収益を持っています。

利益率の向上: NEUの現在の純利益率 (67.7%)は、昨年(1.2%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NEUの収益は過去 5 年間で年間77.4%増加しました。

成長の加速: NEUの過去 1 年間の収益成長率 ( 85270.1% ) は、5 年間の平均 ( 年間77.4%を上回っています。

収益対業界: NEUの過去 1 年間の収益成長率 ( 85270.1% ) はPharmaceuticals業界16%を上回りました。

株主資本利益率

高いROE: NEUの自己資本利益率 ( 76.5% ) は傑出していると考えられます。

Neuren Pharmaceuticals 過去の業績

過去 基準チェック /66

主要情報

最近の業績更新

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Recent updates

Investor sentiment improves as stock rises 16%

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /66